CDEK
← All drugs Report issue

kanamycin

Trade name: Kantrex

Small moleculeapproved

Approved

Feb 13, 1973

Kanamycin A is aminoglycoside anti-bacterial agent. Active against many strains of Gram-negative bacteria and Gram-positive Staphylococcus aureus and epidermis. Some strains of Mycobacterium bacterium are sensitive. Most active in alkaline solution. It binds to bacterial ribosomes and reduces mRNA translation hence reduces protein biosynthesis. However, it also exhibits some toxic effects towards mammalian cells. — NCATS

Clinical trial activity

10 trials · 20 clinical orgs · 14 marketing orgs

Phase 1
2
Phase 2
5
Phase 3
4
Phase 4
1

Earliest trial started Mar 1, 2003 (NCT00042289)

Timeline

1970s

  1. Feb 13, 1973

    Bristol-Myers — Earliest FDA Approval

  2. Feb 13, 1973

    Apothecon — Marketing Organization

  3. Feb 13, 1973

    Bristol-Myers — NDA Organization

1980s

  1. Nov 5, 1981

    West-Ward Pharmaceutical — Marketing Organization

  2. Nov 5, 1981

    Hikma — Marketing Organization

  3. May 9, 1985

    Watson Pharmaceuticals — Marketing Organization

1990s

  1. Jul 31, 1992

    Flaga Group — Marketing Organization

2000s

  1. Dec 17, 2002

    Fresenius — Marketing Organization

  2. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedFeb 13, 1973

Chemistry & pharmacology

Loading structure…

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O
Mol. weight
484.5 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Discontinued

Oral

Yes

Parenteral

Yes

Topical

No

Sources

Also known as

  • 4,6-diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-α-d-glucoside
  • 4,6-diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-α-d-glucoside
  • 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-d-glucopyranoside
  • 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-d-glucopyranoside
  • cantrex
  • cantrex
  • kanacin
  • kanamycin
  • kanamycin
  • kanamycin
  • kanamycin
  • kanamycin
  • kanamycin
  • kanamycin
  • kanamycin
  • kanamycin a
  • kanamycin a
  • kanamycin a
  • kanamycin a sulfate
  • kanamycine
  • kanamycine
  • kanamycin monosulfate
  • kanamycin monosulfate
  • kanamycin monosulfate
  • kanamycin monosulfate
  • kanamycin monosulfate
  • kanamycin monosulfate
  • kanamycin sulfate
  • kanamycin sulfate
  • kanamycin sulfate
  • kanamycin sulfate
  • kannasyn
  • kannasyn
  • kantrex
  • kantrex
  • kantrex
  • kantrim
  • kantrim
  • klebcil
  • klebcil

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03593252N/ASep 1, 2018McMaster University
NCT02975570Phase 3Aug 1, 2017Boston University, University of Florida, Westat
NCT02354014Phase 2May 3, 2016Johnson and Johnson
NCT02409290Phase 3Apr 1, 2016IUATLD, Inc, Medical Research Council
NCT02454205Phase 2/Phase 3 (Phase 3)Oct 1, 2015Stellenbosch University, University of Cape Town, University of Limpopo, Walter Sisulu University
NCT02365623Phase 2Feb 18, 2015Janssen Pharmaceutica NV, Johnson and Johnson
NCT02128308Phase 1Nov 1, 2013Seoul National University
NCT00816426Phase 1Dec 29, 2008Government of Korea, National Institute of Allergy and Infectious Diseases (NIAID), Novartis, University of Ulsan
NCT00508690Phase 3Sep 1, 2007Japan Multinational Trial Organization, National Hospital Organization Kyoto Medical Center
NCT00042289Phase 4Mar 1, 2003Boston University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (20)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boston UniversityAcademic/Hospital2122003
Johnson and JohnsonFor profit2212015
National Institute of Allergy and Infectious Diseases (NIAID)Government2222003
Government of KoreaGovernment1012008
IUATLD, IncAcademic/Hospital1112016
Janssen Pharmaceutica NVFor profit1012015
Japan Multinational Trial OrganizationAcademic/Hospital1112007
McMaster UniversityAcademic/Hospital1112018
Medical Research CouncilGovernment1012016
National Hospital Organization Kyoto Medical CenterAcademic/Hospital1012007
National Institutes of Health (NIH)Government1012003
NovartisFor profit1012008
Seoul National UniversityAcademic/Hospital1112013
Stellenbosch UniversityAcademic/Hospital1012015
University of Cape TownAcademic/Hospital1112015
University of FloridaAcademic/Hospital1012017
University of LimpopoAcademic/Hospital1012015
University of UlsanAcademic/Hospital1012008
Walter Sisulu UniversityAcademic/Hospital1012015
WestatFor profit1012017
20 organizations
Page 1 / 1

Marketing (14)

OrganizationOrg typeRelationshipDate
AbraxisFor profitMKTG—
ApotheconFor profitMKTGFeb 13, 1973
Athenex, Inc.For profitMKTG—
Bristol-MyersFor profitNDAFeb 13, 1973
Flaga GroupFor profitMKTGJul 31, 1992
FreseniusFor profitMKTGDec 17, 2002
HikmaFor profitMKTGNov 5, 1981
International MedicationFor profitMKTG—
King PharmaceuticalsFor profitMKTG—
PharmafairFor profitMKTG—
SOLOPAKFor profitMKTG—
Warner ChilcottFor profitMKTG—
Watson PharmaceuticalsFor profitMKTGMay 9, 1985
West-Ward PharmaceuticalFor profitMKTGNov 5, 1981